Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Nyse MKT  >  CEL-SCI Corporation       US1508374097

 SummaryNewsCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2015 0,35 M
EBIT 2015 -41,2 M
Net income 2015 -
Debt 2015 -
Yield 2015 -
Sales 2016 0,60 M
EBIT 2016 -43,4 M
Net income 2016 -35,9 M
Debt 2016 -
Yield 2016 -
PER 2015 -
PER 2016
Capi. / Sales 2015 208x
Capi. / Sales 2016 121x
Capitalization 72,8 M
More Financials
Company
CEL-SCI Corp. is a biotechnology company, which is involved in the research and development of investigational immunotherapy products for the treatment of cancer and infectious diseases.The company's lead investigational therapy, Multikine, is being developed as a potential therapeutic agent... 
More about the company
Latest news on CEL-SCI CORPORATION
07/06 CEL SCI : Updates on June Patient Enrollment in Its Phase 3 Head and Neck Cancer..
07/01 CEL SCI : NEW STORY CEL-SCI Reports June Patient Enrollment in Its Phase 3 Head ..
07/01 CEL SCI : Reports June Patient Enrollment in Its Phase 3 Head and Neck Cancer Tr..
06/29 CEL-SCI CORPORATION : (NYSE MKT: CVM), Arguably the Most Undervalued Phase III B..
06/29 CEL SCI : NYSE MKT: CVM), Arguably the Most Undervalued Phase III Biotech, is Up..
06/24 CEL SCI : to Present at the 2015 BIO International Convention
06/23 CEL SCI : Submission of Matters to a Vote of Security Holders (form 8-K)
06/17 CEL SCI : is Cleared to Start Patient Enrollment for Its Phase 3 Cancer Immunoth..
More news
Sector news : Bio Therapeutic Drugs
07:31a INCYTE : and Vanderbilt University Medical Center Establish Multi-Year Oncology ..
07:30a GENMAB A/S : Announces European Regulatory Submission for Ofatumumab as Maintena..
06:16a SHANGHAI RAAS BLOOD PRODUCTS : Controller Kicks Off Holding Expansion
More sector news : Bio Therapeutic Drugs
Comments 
Advertisement
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions